about
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot"High resolution melting for mutation scanning of TP53 exons 5-8International network of cancer genome projects.LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancerIdentification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies.Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors.Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Global gene expression profiles of ovarian surface epithelial cells in vivo.Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line--a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia.Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium studyPaclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancerMAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium.Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancerComparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis.Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.Scientists and clinicians test their metal-back to the future with platinum compounds.Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group.Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos.Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcomeHigh levels of genomic aberrations in serous ovarian cancers are associated with better survival.Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patientsObesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitroMolecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome.Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancerIntegrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomasGenome-wide association study for ovarian cancer susceptibility using pooled DNA.
P50
Q21144976-6E87CF8F-2E7D-4C1B-96C1-5DE9492AD614Q21260416-FFF04366-B1DB-406F-A311-A0FBE64C3042Q24611474-DE549342-89AA-4345-BFDB-C94658F12231Q27851868-7C49582C-B744-4CAB-B5C9-3C5CE67BFAC6Q28258903-2FA6A7B4-6B84-433A-A57D-7D32DBAFB9D0Q30252854-E5275458-D474-455F-B90E-B1B5269FF632Q30275068-0F4B2E43-E2C4-49E7-9FC5-057FB97566A6Q30277151-00946DB9-3C2D-4C2A-8DF6-5DDE44624575Q30277784-1B44EA3C-7FD7-4319-A2D5-FD043D9B4624Q30374367-79165988-90CE-4E6A-B195-AFDBD3DABB1EQ33337711-29ABA684-C0AF-49EF-BB78-AEE90FFA3B0FQ33339216-1D648039-3123-4046-8A69-76F00D98B6BAQ33359495-D27F3DE6-5104-4CE7-8552-0876D817E4C7Q33551425-EBA1FBDA-4EC2-44EF-8DD0-5364E8FBCF1CQ33586121-FF2B41A6-772C-44F9-8D1F-54DC0C7FADD5Q33694015-1F286F71-070E-411D-8754-D8F6CED0B843Q33747831-31457DB8-D053-45F9-B427-FCBF7CC734EDQ33847791-FE4AF9B3-EBF3-48A6-B6C9-59DF8B8AE71AQ33851325-AC3B2826-DC3E-4D71-A104-62A922A3B405Q33886925-DF0DC479-979D-4359-A50A-6102567908DDQ33947899-673949C0-332A-430D-AAB4-7594E3C52A44Q34103978-C25CE9D2-784D-4E38-8C04-3A6524252878Q34133677-3629C217-A6A0-4F8A-A8F7-3C0332A4F3E2Q34181986-8FD4856E-225F-4625-B285-3F78EAC4E019Q34339207-34CE7255-926D-4A9A-9E70-037F163E1CA1Q34381630-E7BF7D42-32A9-42E8-9709-C8680915D329Q34571142-E2BE142F-F8F1-41F8-A09A-1216218EC1F7Q34687073-2982A785-A9C8-4582-AC74-663243A518C5Q34871343-FCD28632-8F04-4B4A-91DC-5272D1EFF314Q35177861-C56EAFAA-6242-4190-8F83-BAD9F927FF8EQ36027025-7EDD9D5B-79D0-45BF-B8A2-D54C18F698C1Q36145443-2A219CC2-3BE1-423F-98D2-61D2946D9D9AQ36218993-5A392CBD-317D-4B4A-943D-3502A1B44CF3Q36497294-49428D07-5B8C-4E36-AED7-2D3BC25206A2Q36510142-312915E1-1305-4949-94CB-DA3043BD43CEQ36545843-EF0DF799-D622-44D5-9443-578FF41563BFQ36831854-16B8007E-D66A-4060-9A3B-F06CA7C0C005Q36916243-17403F4B-F502-4A06-A010-6A134BE745C5Q37161861-501EECE8-903A-4309-8ABC-BBD6FC87E27BQ37202841-CDE0D06A-5D39-4649-927E-C2BB7979002D
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anna deFazio
@ast
Anna deFazio
@en
Anna deFazio
@es
Anna deFazio
@nl
type
label
Anna deFazio
@ast
Anna deFazio
@en
Anna deFazio
@es
Anna deFazio
@nl
altLabel
Anna DeFazio
@en
prefLabel
Anna deFazio
@ast
Anna deFazio
@en
Anna deFazio
@es
Anna deFazio
@nl
P1053
D-3939-2013
P106
P1153
56709413800
P21
P31
P496
0000-0003-0057-4744